This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEH8Q0KR_L.jpg
TOKYO (Reuters) – Japan has approved GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.
